174 related articles for article (PubMed ID: 38264964)
1. Liprin-α1 contributes to oncogenic MAPK signaling by counteracting ERK activity.
Pehkonen H; Filippou A; Väänänen J; Lindfors I; Vänttinen M; Ianevski P; Mäkelä A; Munne P; Klefström J; Toppila-Salmi S; Grénman R; Hagström J; Mäkitie AA; Karhemo PR; Monni O
Mol Oncol; 2024 Mar; 18(3):662-676. PubMed ID: 38264964
[TBL] [Abstract][Full Text] [Related]
2. Liprin-α1 modulates cancer cell signaling by transmembrane protein CD82 in adhesive membrane domains linked to cytoskeleton.
Pehkonen H; Lento M; von Nandelstadh P; Filippou A; Grénman R; Lehti K; Monni O
Cell Commun Signal; 2018 Jul; 16(1):41. PubMed ID: 30005669
[TBL] [Abstract][Full Text] [Related]
3. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
Hoang VT; Nyswaner K; Torres-Ayuso P; Brognard J
J Biol Chem; 2020 Jun; 295(25):8470-8479. PubMed ID: 32358059
[TBL] [Abstract][Full Text] [Related]
4. Liprin-α1 is a regulator of vimentin intermediate filament network in the cancer cell adhesion machinery.
Pehkonen H; von Nandelstadh P; Karhemo PR; Lepikhova T; Grenman R; Lehti K; Monni O
Sci Rep; 2016 Apr; 6():24486. PubMed ID: 27075696
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1.
Shen JC; Unoki M; Ythier D; Duperray A; Varticovski L; Kumamoto K; Pedeux R; Harris CC
Cancer Res; 2007 Mar; 67(6):2552-8. PubMed ID: 17363573
[TBL] [Abstract][Full Text] [Related]
6. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
7. Effects of the scaffold proteins liprin-α1, β1 and β2 on invasion by breast cancer cells.
Chiaretti S; Astro V; Chiricozzi E; de Curtis I
Biol Cell; 2016 Mar; 108(3):65-75. PubMed ID: 26663347
[TBL] [Abstract][Full Text] [Related]
8. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
Romerio F; Riva A; Zella D
Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
[TBL] [Abstract][Full Text] [Related]
10. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
11. Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos PI; Solit DB
Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
[TBL] [Abstract][Full Text] [Related]
12. DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways.
Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Fujita S
Int J Oncol; 2019 Mar; 54(3):1021-1032. PubMed ID: 30569110
[TBL] [Abstract][Full Text] [Related]
13. Liprin-α1 regulates breast cancer cell invasion by affecting cell motility, invadopodia and extracellular matrix degradation.
Astro V; Asperti C; Cangi MG; Doglioni C; de Curtis I
Oncogene; 2011 Apr; 30(15):1841-9. PubMed ID: 21151172
[TBL] [Abstract][Full Text] [Related]
14. Role of Liprins in the Regulation of Tumor Cell Motility and Invasion.
Chiaretti S; de Curtis I
Curr Cancer Drug Targets; 2016; 16(3):238-48. PubMed ID: 26882029
[TBL] [Abstract][Full Text] [Related]
15. Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways.
Granda-Díaz R; Manterola L; Hermida-Prado F; Rodríguez R; Santos L; García-de-la-Fuente V; Fernández MT; Corte-Torres MD; Rodrigo JP; Álvarez-Teijeiro S; Lawrie CH; Garcia-Pedrero JM
Biomed Pharmacother; 2023 May; 161():114512. PubMed ID: 36931033
[TBL] [Abstract][Full Text] [Related]
16. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence.
Wang W; Chen JX; Liao R; Deng Q; Zhou JJ; Huang S; Sun P
Mol Cell Biol; 2002 May; 22(10):3389-403. PubMed ID: 11971971
[TBL] [Abstract][Full Text] [Related]
17. Small G proteins Rac1 and Ras regulate serine/threonine protein phosphatase 5 (PP5)·extracellular signal-regulated kinase (ERK) complexes involved in the feedback regulation of Raf1.
Mazalouskas MD; Godoy-Ruiz R; Weber DJ; Zimmer DB; Honkanen RE; Wadzinski BE
J Biol Chem; 2014 Feb; 289(7):4219-32. PubMed ID: 24371145
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
19. VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer.
Fernández IF; Blanco S; Lozano J; Lazo PA
Mol Cell Biol; 2010 Oct; 30(19):4687-97. PubMed ID: 20679487
[TBL] [Abstract][Full Text] [Related]
20. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
